Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells.

Borland MK, Trimmer PA, Rubinstein JD, Keeney PM, Mohanakumar K, Liu L, Bennett JP Jr.

Mol Neurodegener. 2008 Dec 29;3:21. doi: 10.1186/1750-1326-3-21.

2.

Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.

Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL.

Brain. 2005 Nov;128(Pt 11):2654-64. Epub 2005 Jul 6.

3.

α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment.

George S, Mok SS, Nurjono M, Ayton S, Finkelstein DI, Masters CL, Li QX, Culvenor JG.

J Mol Neurosci. 2010 Oct;42(2):243-54. doi: 10.1007/s12031-010-9378-1. Epub 2010 May 13.

PMID:
20464527
4.

D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease.

Imamura K, Takeshima T, Kashiwaya Y, Nakaso K, Nakashima K.

J Neurosci Res. 2006 Nov 1;84(6):1376-84.

PMID:
16917840
5.

Mechanism of toxicity in rotenone models of Parkinson's disease.

Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT.

J Neurosci. 2003 Nov 26;23(34):10756-64.

7.

Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology.

Conn KJ, Gao W, McKee A, Lan MS, Ullman MD, Eisenhauer PB, Fine RE, Wells JM.

Brain Res. 2004 Oct 1;1022(1-2):164-72.

PMID:
15353226
8.

Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.

Testa CM, Sherer TB, Greenamyre JT.

Brain Res Mol Brain Res. 2005 Mar 24;134(1):109-18. Epub 2005 Jan 6.

PMID:
15790535
9.

Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells.

Sherer TB, Trimmer PA, Borland K, Parks JK, Bennett JP Jr, Tuttle JB.

Brain Res. 2001 Feb 9;891(1-2):94-105.

PMID:
11164812
10.
11.

SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease.

Xie HR, Hu LS, Li GY.

Chin Med J (Engl). 2010 Apr 20;123(8):1086-92. Review.

12.

An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT.

J Neurosci. 2002 Aug 15;22(16):7006-15.

13.

An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells.

Shamoto-Nagai M, Maruyama W, Kato Y, Isobe K, Tanaka M, Naoi M, Osawa T.

J Neurosci Res. 2003 Nov 15;74(4):589-97.

PMID:
14598303
14.
15.

MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells.

Gómez-Santos C, Ferrer I, Reiriz J, Viñals F, Barrachina M, Ambrosio S.

Brain Res. 2002 May 10;935(1-2):32-9.

PMID:
12062470
16.

Rotenone induces apoptosis via activation of bad in human dopaminergic SH-SY5Y cells.

Watabe M, Nakaki T.

J Pharmacol Exp Ther. 2004 Dec;311(3):948-53. Epub 2004 Jul 27.

17.

Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease.

Xiong N, Huang J, Zhang Z, Zhang Z, Xiong J, Liu X, Jia M, Wang F, Chen C, Cao X, Liang Z, Sun S, Lin Z, Wang T.

PLoS One. 2009 Nov 18;4(11):e7878. doi: 10.1371/journal.pone.0007878.

18.

The cybrid model of sporadic Parkinson's disease.

Trimmer PA, Bennett JP Jr.

Exp Neurol. 2009 Aug;218(2):320-5. doi: 10.1016/j.expneurol.2009.03.016. Epub 2009 Mar 26. Review.

19.
Items per page

Supplemental Content

Write to the Help Desk